drugset / Trial / NCT06916884

Confirmatory Study on the Efficacy and Safety of the Fixed-dose Combination of Desloratadine/Betamethasone Versus Desloratadine

NCT06916884

Phase 3 Recruiting 70 enrolled Laboratorios Silanes S.A. de C.V.
RandomizedParallel-groupDouble-blindTreatment

Summary

Phase IIIb , longitudinal, multicenter, randomized, double-blind, to evaluate efficacy and safety of the fixed-dose combination of Desloratadine 5 mg / Betamethasone 0.25 mg versus Desloratadine 5 mg monotherapy as treatment for symptoms associated with allergic rhinitis.

Timeline

Start
2024-11-11
Primary completion
2025-05-11
Completion
2025-06-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Betamethasone Other / unclassified 0.25 mg Oral
Comparator Desloratadine Small molecule 5 mg Oral

Indications